Literature DB >> 35140012

Target Diseases for Neonatal Screening in Germany.

Ute Spiekerkoetter1, Heiko Krude.   

Abstract

BACKGROUND: Neonatal screening in Germany currently comprises 19 congenital diseases, 13 of which are metabolic diseases. Approximately one in 1300 newborns suffers from one of these target diseases. Early diagnosis and treatment enable the affected children to undergo better development and even, in many cases, to have a normal life.
METHODS: This review is based on pertinent publications retrieved by a selective search in the PubMed and Embase databases.
RESULTS: Positive screening findings are confirmed in approximately one out of five newborns. The prompt evaluation of suspected diagnoses is essential, as treatment for some of these diseases must be initiated immediately after birth to prevent longterm sequelae. The most commonly identified diseases are primary hypothyroidism (1:3338), phenylketonuria/hyperphenylalaninemia (1 : 5262), cystic fibrosis (1 : 5400), and medium-chain acyl-CoA dehydrogenase deficiency (1 : 10 086). Patient numbers are rising as new variants of the target diseases are being identified, and treatments must be adapted to their heterogeneous manifestations. Precise diagnosis and the planning of treatment, which is generally lifelong, are best carried out in a specialized center.
CONCLUSION: Improved diagnosis and treatment now prolong the lives of many patients with congenital diseases. The provision of appropriate long-term treatment extending into adulthood will be a central structural task for screening medicine in the future.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35140012      PMCID: PMC9450505          DOI: 10.3238/arztebl.m2022.0075

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   8.251


  27 in total

1.  Lethal Undiagnosed Very Long-Chain Acyl-CoA Dehydrogenase Deficiency with Mild C14-Acylcarnitine Abnormalities on Newborn Screening.

Authors:  U Spiekerkoetter; M Mueller; M Sturm; M Hofmann; D T Schneider
Journal:  JIMD Rep       Date:  2012-02-26

2.  Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.

Authors:  Melanie B Gillingham; Stephen B Heitner; Julie Martin; Sarah Rose; Amy Goldstein; Areeg Hassan El-Gharbawy; Stephanie Deward; Michael R Lasarev; Jim Pollaro; James P DeLany; Luke J Burchill; Bret Goodpaster; James Shoemaker; Dietrich Matern; Cary O Harding; Jerry Vockley
Journal:  J Inherit Metab Dis       Date:  2017-09-04       Impact factor: 4.982

3.  Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Louise Frisén; Christina Norrby; Angelica Lindén Hirschberg; Catarina Almqvist; Agneta Nordenskjöld; Anna Nordenström
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

4.  Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-29       Impact factor: 4.982

5.  Screening of Newborns for Disorders with High Benefit-Risk Ratios Should Be Mandatory.

Authors:  Nicole Kelly; Dalia Chehayeb Makarem; Melissa P Wasserstein
Journal:  J Law Med Ethics       Date:  2016-06       Impact factor: 1.718

Review 6.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 7.  Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism - a systematic review.

Authors:  Nina A Zeltner; Martina Huemer; Matthias R Baumgartner; Markus A Landolt
Journal:  Orphanet J Rare Dis       Date:  2014-10-25       Impact factor: 4.123

Review 8.  Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.

Authors:  Michael Pugliese; Kylie Tingley; Andrea Chow; Nicole Pallone; Maureen Smith; Alvi Rahman; Pranesh Chakraborty; Michael T Geraghty; Julie Irwin; Laure Tessier; Stuart G Nicholls; Martin Offringa; Nancy J Butcher; Ryan Iverson; Tammy J Clifford; Sylvia Stockler; Brian Hutton; Karen Paik; Jessica Tao; Becky Skidmore; Doug Coyle; Kathleen Duddy; Sarah Dyack; Cheryl R Greenberg; Shailly Jain Ghai; Natalya Karp; Lawrence Korngut; Jonathan Kronick; Alex MacKenzie; Jennifer MacKenzie; Bruno Maranda; John J Mitchell; Murray Potter; Chitra Prasad; Andreas Schulze; Rebecca Sparkes; Monica Taljaard; Yannis Trakadis; Jagdeep Walia; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2020-01-14       Impact factor: 4.123

Review 9.  Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app.

Authors:  Eva M M Hoytema van Konijnenburg; Saskia B Wortmann; Marina J Koelewijn; Laura A Tseng; Roderick Houben; Sylvia Stöckler-Ipsiroglu; Carlos R Ferreira; Clara D M van Karnebeek
Journal:  Orphanet J Rare Dis       Date:  2021-04-12       Impact factor: 4.123

10.  A novel tandem mass spectrometry method for rapid confirmation of medium- and very long-chain acyl-CoA dehydrogenase deficiency in newborns.

Authors:  Frank ter Veld; Martina Mueller; Simone Kramer; Ulrike Haussmann; Diran Herebian; Ertan Mayatepek; Maurice D Laryea; Sonja Primassin; Ute Spiekerkoetter
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.